MARKET

KARD

KARD

Kardigan, Inc.
NASDAQ
18.69
-0.99
-5.03%
After Hours: 18.69 0 0.00% 19:30 09/10 EDT
OPEN
19.85
PREV CLOSE
19.68
HIGH
20.04
LOW
18.69
VOLUME
433.15K
TURNOVER
--
52 WEEK HIGH
27.00
52 WEEK LOW
16.25
MARKET CAP
1.75B
P/E (TTM)
-3.5662
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KARD last week (0831-0904)?
Weekly Report · 4d ago
6 Biotech Stocks To Watch Ahead Of Key Catalysts: RenovoRx, Eupraxia, Connect Bio, Kardigan & More
NASDAQ · 09/03 03:20
Kardigan’s Tonlamarsen Trial Targets Severe Hypertension: What Investors Should Watch
TipRanks · 09/02 16:30
Kardigan’s Danicamtiv Heart Study Moves Forward, Keeping KARD on Investors’ Radar
TipRanks · 09/02 16:30
Kardigan to Present at Two September Investor Conferences
Barchart · 09/02 15:05
Weekly Report: what happened at KARD last week (0824-0828)?
Weekly Report · 08/31 10:40
Kardigan Is Maintained at Overweight by JP Morgan
Dow Jones · 08/25 13:06
Kardigan Price Target Cut to $46.00/Share From $51.00 by JP Morgan
Dow Jones · 08/25 13:06
More
About KARD
Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.

Webull offers Kardigan, Inc. stock information, including NASDAQ: KARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KARD stock methods without spending real money on the virtual paper trading platform.